Biosimilar Lucentis Sponsors Had To Navigate Different FDA, EMA Requirements
Executive Summary
European Medicines Agency insisted on a stricter statistical analysis than the US FDA for demonstrating equivalence on the primary endpoint for both Coherus/BioEq’s Cimerli and Samsung Bioepis’ Byooviz; there also were differences in the regulators' preferred primary analysis population and primary endpoint interval.
You may also be interested in...
Stada, Biogen Bring Greater Ranibizumab Competition To EU And UK
April brings news of further biosimilar competition to Lucentis in major European markets.
Samsung Bioepis Scoops First EU Lucentis Biosimilar As 2022 Date Looms
Samsung Bioepis has seen a positive opinion in the EU for its Byooviz (ranibizumab) biosimilar treatment for wet age-related macular degeneration turned into final approval by the European Commission. The company is also leading the pack in the US.
CAR-T Malignancy Reports Could Temper Excitement For Use Beyond Oncology
US FDA has received a total of 19 reports of T-cell malignancy involving BCMA- or CD19-directed autologous CAR-T cell immunotherapies and is evaluating the need for regulatory action. Focus on lentiviral and retroviral vectors could extend to safety of other types of gene therapies.